tella, Inc.
tella, Inc.
Aktie · JP3545900007 (XTKS)
Übersicht
Kein Kurs
n/a
Firmenprofil zu tella, Inc. Aktie
tella, Inc. researches and develops regenerative and cell medicines. The company offers techniques and operational knowhow associated with dendritic cell vaccine therapy to affiliated medical institutions for the treatment of cancer. It is also involved in the provision of consultation services on the establishment and maintenance of cell processing centers, and on introduction of management systems for cell cultivation; and lease of standard operating procedure and regular checks on manufacturing operation management and training of cell cultivation technicians. In addition, the company provides consultation services on training of expertise regarding treatment practice; and support services for the assessment of therapies, documentation required for treatment practice, and cognition and information providing activities for physicians and patients. tella, Inc. was founded in 2004 and is based in Tokyo, Japan.
Erhalte tagesaktuelle Insights vom finAgent über tella, Inc.

Unternehmensdaten

Name tella, Inc.
Firma tella, Inc.
Website https://www.tella.jp
Heimatbörse XTKS Tokyo
ISIN JP3545900007
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Yuichiro Yazaki
Land Japan
Währung JPY
Mitarbeiter 0,0 T
Adresse Mitsuihanagiri Building, 160-0023 Tokyo
IPO Datum 2009-03-26

Ticker Symbole

Name Symbol
Tokyo 2191.T
Weitere Aktien
Investoren, die tella, Inc. halten, haben auch folgende Aktien im Depot:
Alfio Bardolla Training Group S.p.A.
Alfio Bardolla Training Group S.p.A. Aktie
PFZ.SCHW.KTB 22/30
PFZ.SCHW.KTB 22/30 Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025